Welcome to the Shield Toolkit
To support your efforts in educating employees on the importance of colorectal cancer (CRC) screening and the availability of Shield as an option for CRC screening, this toolkit contains ready-to-use materials, product language and images. Screening can detect colorectal cancer early, when it’s most treatable. You may use the materials below to educate clinical staff and employees (patients) on CRC screening, and to learn about the Shield blood-based screening test and integrated screening program options.
How to access the digital items:
Click on one of the 4 categories to display the list of downloadable documents within that category. Next, click on an item to view and download.
Use these materials to talk about Shield blood-based screening and CRC.
Language Guide
Use these materials to educate and create awareness to your employees about CRC and to promote Shield™ as an option for colorectal cancer screening through digital campaigns, posters, or mailers. These materials can be branded with or without your logo.
Use these materials to prepare for your promotion for recruitment and hosting for on-site Shield TM screening event. These materials can be branded with or without your logo. To schedule a screening event please contact your account director or email getscreened@guardanthealth.com for next steps.
Recruitment
Screening Day
You may use these materials when working with your worksite health clinic to communicate next steps to employees, educate clinic and admininistrative staff and create email templates for marketing campaigns. These materials can be branded with or without your logo.
Employee (Patients)
Clinicians and staff
The information contained on this webpage is intended for healthcare providers who use Shield blood-based screening tests in their practices.
Shield™ is a qualitative laboratory developed test intended to detect colorectal neoplasia by identifying genomic and epigenomic alterations in cell-free DNA in plasma from blood collected in Guardant blood collection tubes.
- The assay is intended to be complementary to and not a replacement for current recommended colorectal cancer screening methods
- Patients with an "abnormal signal detected" Shield test result should be referred for colonoscopic evaluation
- A "normal signal detected" Shield test result does not preclude the presence of colorectal neoplasia, and patients should continue participating in guideline-recommended screening programs
- Shield was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. This test has not been cleared or approved by the US FDA
